恶性胶质瘤的放射免疫治疗

高云朝

恶性胶质瘤的放射免疫治疗

高云朝

文章导航 > 国际放射医学核医学杂志 > 2004, 28 > 4: (149-152)

引用本文:

Citation:

恶性胶质瘤的放射免疫治疗

高云朝

200040 上海, 复旦大学附属华山医院核医学科
中图分类号: R817.5

Radioimmunotherapy for malignant glioma

GAO Yun-chao

Department of Nuclear Medicine, Huashan Hospital, Fudan University, Shanghai 200040, China
CLC number: R817.5

摘要: 恶性胶质瘤以手术切除为主,辅以放疗和化疗,在此基础上再进行适当的放射免疫治疗,可进一步延长生存期。¹³¹I和⁹⁰Y标记的抗腱生蛋白抗体用于恶性胶质瘤的实验和临床Ⅰ、Ⅱ期治疗研究获得了满意效果。
- 胶质瘤 /
- 放射免疫治疗 /
- 抗腱生蛋白单抗
Abstract: Malignant glioma is treated mainly by surgery with chemotherapy and external radiotherapy as adjuvant remedies. Survival time can be prolonged if appropriate radioimmunotherapy is employed as another concurrent alternative. Per-clinical, clinical phase I and II studies of ¹³¹I and ⁹⁰Y labeled anti-tenascin monoclonal antibodies in the treatment of malignant glioma have resulted in satisfactory therapeutic efficacy.
- glioma /
- radioimmunotherapy /
- anti-tenascin monoclonal antibodies
本作品遵循Signature-Non-Commercial Use 4.0 International (CC BY-NC 4.0)协议

[1]	Riva P,Franceschi G,Frattarelli M,et al.¹³¹I radioconjugated antibodies for the locoregional radioimmunotherapy of high-grade malig-nant glioma:Phase I and II Study[J].Acta Oncologica,1999,38(3):351-359.
[2]	Riva P,Franceschi G,Riva N,et al.Role of nuclear medicine in the treatment of malignant gliomas:the locoregional radioimmunotherapy approach[J].Eur J Nucl Med,2000,27(5):601-609.
[3]	Santis RD,Anastasi AM,alessio VD.et al. Novel antitenascin antibody with increased tumour localisation for pretargeted antibodyguided radioimmunotherapy (PAGRITR^R)[J].Br J Cancer,2003,88(07):996-1003.
[4]	Akabani G,Cokgor I,Coleman RE,et al.Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy[J].Int J Radia Oncol Biol Phys,2000,46(4):947-958.
[5]	Cokgor I,Akabani G,Kuan CT,et al.Phase I trial results of iodine-131 labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas[J].J Clin Oncol,2000,18(22):3862-3872.
[6]	Goetz C,Rive P,Poepperl G,et al.Locoregional radioimmunotherapy in selected patients with malignant glioma:experience,side effects and survival times[J].J Neuro Oncol,2003,62:321-328.
[7]	Mahesparan R,Read TA,Lund-Johansen M,et al.Expression of extracellular matrix components in a highly infiltrative in vivo glioma model[J].Acta Neuropathologica,2003,105(1):49-57.
[8]	Akabani G,Reist CJ,Cokgor I,et al.Dosimetry of ¹³¹I-labeled 81C6 monoclonal antibody administered into surgically created resection cavities in patients with malignant brain tumors[J]. J Nucl Med,1999,40(4):631-638.
[9]	Hasegawa K,Yoshida T,Matsumoto K,et al.Differential expression of tenascin-C and tenascin-X in human astrocytomas[J].Acta Neu-ropathologica,1997,93:431-437.
[10]	Popperl G,Gotz C,Gildehaus FJ,et al.Initial experiences with adjuvant locoregional radioimmunotherapy using ¹³¹I-labeled monoclonal antibodies against tenascin(BC-4) for treatment of glioma (WHO IIIand TV)[J].Nuklearmedizin,2002,41(3):120-128.
[11]	Reardon DA,Akabani G,Edward CR,et al.Phase II trial of murine ¹³¹I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas[J].J Clin Oncol,2002,20(5):1389-1397.
[12]	Hopkins K,Chandler C,Eatough J,et al.Direct injection of ⁹⁰Y-MoAbs into glioma tumor resection cavities leads to limited diffusion of the radioimmunoconjugates into normal brain parenchyma:a model to estimate absorbed radiation dose[J].Int J Radiat Oncol Biol Phys,1998,40(4):835-844.
[13]	Riva P,Franceschi G,Frattarelli M,et al.Loco-regional radioimmunotherapy of high-grade malignant gliomas using specific monoclonal antibodies labeled with ⁹⁰Y:a Phase I study[J].Clin Cancer Res,1999,5:3275s-3280s.
[14]	Paganelli G,Grana C,Chinol M,et al.Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin[J].Eur J Nucl Med,1999,26(4):348-357.
[15]	Grana C,Chinol M,Robertson C.Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients:a pilot study[J].Br J Cancer,2002,86:207-212.
[16]	Hauck ML,Larsen RH,Welsh PC,et al.Cytotoxicity of α-particle emitting astatine-211-labelled antibody in tumour spheroids:no effect of hyperthermia[J].Br J Cancer,1998,77(5):753-759.
[17]	Zalutsky MR,Zhao XG,Alston KL,et al.High-level production of α-particle emitting ²¹¹At and preparation of ²¹¹At labeled antibodies for clinical use[J].J Nucl Med,2001,42(10):1508-1515.
[18]	Imam SK.Advancement in cancer therapy with alpha-emitters:a review[J].Int J Radiat Oncol Biol Phys,2001,51(1):271-278.

[1]	陈立波 , 朱瑞森 . Bexxar治疗非霍奇金淋巴瘤的研究现状. 国际放射医学核医学杂志, 2005, 29(2): 67-70.
[2]	刘影 , 李传福 . 功能性磁共振成像在胶质瘤中的应用. 国际放射医学核医学杂志, 2005, 29(3): 143-145.
[3]	袁志斌 . Zevalin^TM:一种放射免疫治疗新药. 国际放射医学核医学杂志, 2002, 26(5): 225-227.
[4]	李敏杰 . 胰腺癌的放射免疫治疗进展. 国际放射医学核医学杂志, 2003, 27(4): 154-156.
[5]	田嘉禾 . 关于放射免疫治疗的新思考. 国际放射医学核医学杂志, 1997, 21(z1): 249-252.
[6]	宁静 , 于鹏 , 刘家金 , 党浩丹 , 徐白萱 . ¹⁸F-FDG PET/CT图像的影像组学分析在胶质瘤MGMT基因甲基化状态评估中的初步应用. 国际放射医学核医学杂志, 2020, 44(8): 486-492. doi: 10.3760/cma.j.cn121381-201903057-00064
[7]	薛景 , 刘芬菊 . PI3K/Akt与胶质瘤辐射抗性. 国际放射医学核医学杂志, 2005, 29(1): 40-43.
[8]	田源 , 张良安 . 放射免疫治疗中的α核素微剂量研究. 国际放射医学核医学杂志, 2006, 30(1): 39-41.
[9]	任均田 , 林学颜 . 放射免疫显像与治疗的应用进展. 国际放射医学核医学杂志, 1995, 19(2): 57-59.
[10]	杨卫东 , 汪静 . 肿瘤核素靶向治疗新进展. 国际放射医学核医学杂志, 2015, 39(1): 19-24, 36. doi: 10.3760/cma.j.issn.1673-4114.2015.01.006